NCT00000152|UnknownPhase 3
Loading search results
Sponsor study identifier
interventional
N/A
0 countries
N/A
Study Start
April 1982
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
Not reported
Date not reportedStudy Completion
Not reported
Date not reportedTo determine whether 50 mg of beta-carotene taken every other day reduces the risk of developing age-related macular degeneration (AMD) among male U.S. physicians who were aged 40 to 84 in 1982. To investigate the possible relationship of AMD with other antioxidants, including selenium and vitamins A, C, and E. To identify potential risk factors for development of AMD. Possible risk factors include height, systemic hypertension, cardiovascular disease, blood cholesterol, cigarette smoking, iris and skin color, sunlight exposure, body mass index, diabetes, and alcohol intake.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Not reported
Date not reportedClick on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
April 1982
Date type not reportedThis date has not been verified as actual or estimated.
September 23, 1999
Actual (reported)September 24, 1999
Actual (reported)Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.
Christen WG, Manson JE, Glynn RJ, Gaziano JM, Chew EY, Buring JE, Hennekens CH. Beta carotene supplementation and age-related maculopathy in a randomized trial of US physicians. Arch Ophthalmol. 2007 Mar;125(3):333-9. doi: 10.1001/archopht.125.3.333.
First Submitted
September 23, 1999
First Posted
September 24, 1999
Study Start
April 1982
Date type not reportedThis date has not been verified as actual or estimated.
Last Updated
June 24, 2005
Record last verified: 2001-09
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved:
Extension Study of rhuFab V2 in Subjects With Neovascular Age-Related Macular Degeneration (AMD)